References

Vaccination against respiratory pseudomonas aeruginosa infection

10.4161/hv.34296 · 2015 · External reference

Targeting the type three secretion system in pseudomonas aeruginosa

10.1016/j.tips.2016.05.011 · 2016 · External reference

Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics

2017 · External reference

2049. National trends in infections caused by pseudomonas aeruginosa and carbapenem resistant pseudomonas aeruginosa, 2017 – 2020

10.1093/ofid/ofac492.1671 · 2022 · External reference

Current trends in the epidemiology of multidrug-resistant and beta-lactamase-producing pseudomonas aeruginosa in Asia and Africa: A systematic review and meta-analysis

10.7717/peerj.18986 · 2025 · External reference

Who bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance

2024 · External reference

Cystic fibrosis and pseudomonas aeruginosa: The host-microbe interface

10.1128/cmr.00138-18 · 2019 · External reference

Cystic fibrosis lung environment and pseudomonas aeruginosa infection

10.1186/s12890-016-0339-5 · 2016 · External reference

Mortality in bronchiectasis: A long-term study assessing the factors influencing survival

10.1183/09031936.00003709 · 2009 · External reference

Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease

10.1159/000331224 · 2011 · External reference

Clinical implications of pseudomonas aeruginosa colonization in chronic obstructive pulmonary disease patients

10.15326/jcopdf.2024.0582 · 2025 · External reference

Progress toward the elusive pseudomonas aeruginosa vaccine

10.1089/sur.2018.233 · 2018 · External reference

Immunological considerations in the development of pseudomonas aeruginosa vaccines

10.1080/21645515.2019.1650999 · 2020 · External reference

Enhanced annotations and features for comparing thousands of pseudomonas genomes in the pseudomonas genome database

10.1093/nar/gkv1227 · 2016 · External reference

The v antigen of pseudomonas aeruginosa is required for assembly of the functional popb/popd translocation pore in host cell membranes

10.1128/iai.72.8.4741-4750.2004 · 2004 · External reference

Development of a broadly protective, self-adjuvanting subunit vaccine to prevent infections by pseudomonas aeruginosa

10.3389/fimmu.2020.583008 · 2020 · External reference

The a subunit of escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes igg2a, iga, and th17 responses to vaccine antigens

10.1128/iai.00181-12 · 2012 · External reference

Development of a nano-emulsion based multivalent protein subunit vaccine against pseudomonas aeruginosa

10.3389/fimmu.2024.1372349 · 2024 · External reference

Understanding pseudomonas aeruginosa-host interactions: The ongoing quest for an efficacious vaccine

10.3390/cells9122617 · 2020 · External reference

Effectiveness and immunogenicity of a nanoemulsion protein subunit vaccine against pseudomonas aeruginosa: Investigation in diet-induced obese mice

10.1093/jimmun/vkag052 · 2026 · External reference

Key roles of adjuvants in modern vaccines

10.1038/nm.3409 · 2013 · External reference

Respiratory mucosal vaccines: Applications, delivery strategies and design considerations

10.1016/j.biopha.2025.118326 · 2025 · External reference

Novel lipid a mimetics, becc438 and becc470, act as potent adjuvants in bacterial and viral subunit vaccines

10.4049/jimmunol.204.supp.166.14 · 2020 · External reference

Enhancing protective efficacy and immunogenicity of hemagglutinin-based influenza vaccine utilizing adjuvants developed by becc

10.1101/2025.06.03.657703 · 2025 · External reference

A lipid a-based tlr4 mimetic effectively adjuvants a yersinia pestis rf-v1 subunit vaccine in a murine challenge model

10.1016/j.vaccine.2018.05.101 · 2018 · External reference

Enhancing the protection of influenza virus vaccines with becc tlr4 adjuvant in aged mice

10.1038/s41598-023-27965-x · 2023 · External reference

Physicochemical characterization of biological and synthetic forms of two lipid a-based tlr4 agonists

10.1016/j.heliyon.2023.e18119 · 2023 · External reference

Rationally designed tlr4 ligands for vaccine adjuvant discovery

10.1128/mbio.00492-17 · 2017 · External reference

Novel tlr4 adjuvant elicits protection against homologous and heterologous influenza a infection

10.1016/j.vaccine.2021.06.085 · 2021 · External reference

Intranasal vlp-rbd vaccine adjuvanted with becc470 confers immunity against delta sars-cov-2 challenge in k18-hace2-mice

10.1016/j.vaccine.2023.06.080 · 2023 · External reference

Effect of two unique nanoparticle formulations on the efficacy of a broadly protective vaccine against pseudomonas aeruginosa

10.3389/fphar.2021.706157 · 2021 · External reference

Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants

10.1080/21645515.2015.1046660 · 2015 · External reference

Impact of the tlr4 agonist becc438 on a novel vaccine formulation against shigella spp

10.3389/fimmu.2023.1194912 · 2023 · External reference

Broadly protective shigella vaccine based on type iii secretion apparatus proteins

10.1128/iai.06174-11 · 2012 · External reference

Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to streptococcus pneumoniae type 3

10.1128/iai.71.12.6915-6920.2003 · 2003 · External reference

Vaccines for pseudomonas aeruginosa: A long and winding road

10.1586/14760584.2014.890053 · 2014 · External reference

Resistance of mucoid pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro

10.1128/iai.56.12.3173-3179.1988 · 1988 · External reference

Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease

10.1016/j.vaccine.2009.04.066 · 2009 · External reference

Multicomponent pseudomonas aeruginosa vaccines eliciting th17 cells and functional antibody responses confer enhanced protection against experimental acute pneumonia in mice

10.1128/iai.00203-22 · 2022 · External reference

The unfulfilled potential of mucosal immunization

10.1016/j.jaci.2022.05.002 · 2022 · External reference

Advances and prospects of respiratory mucosal vaccines: Mechanisms, technologies, and clinical applications

10.1038/s41541-025-01280-0 · 2025 · External reference

A protein subunit vaccine elicits a balanced immune response that protects against pseudomonas pulmonary infection

10.1038/s41541-023-00618-w · 2023 · External reference

Vaccination of mice with hybrid protein containing exotoxin s and pcrv with adjuvants alum and mpl protects pseudomonas aeruginosa infections

10.1038/s41598-022-05157-3 · 2022 · External reference

Pseudomonas aeruginosa: Recent advances in vaccine development

10.3390/vaccines10071100 · 2022 · External reference

Functional assays to evaluate antibody-mediated responses against shigella: A review

10.3389/fcimb.2023.1171213 · 2023 · External reference

Opsonophagocytic killing assay to assess immunological responses against bacterial pathogens

10.3791/59400 · 2019 · External reference

Development of an opsonophagocytic killing assay using hl-60 cells for detection of functional antibodies against streptococcus pyogenes

10.1128/msphere.00617-18 · 2018 · External reference

Mucosal immunity and vaccination strategies: Current insights and future perspectives

10.1186/s43556-025-00301-7 · 2025 · External reference

Antibody-independent, interleukin-17a-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide

10.1128/iai.74.4.2187-2195.2006 · 2006 · External reference

Tlr4 mediates vaccine-induced protective cellular immunity to bordetella pertussis: Role of il-17-producing t cells

10.4049/jimmunol.177.11.7980 · 2006 · External reference

Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces Il-17-secreting T(Rm) cells

10.1038/s41385-018-0080-x · 2018 · External reference

Roles of Il-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy

10.1002/jlb.5mir0420-055r · 2020 · External reference

Directing transition from innate to acquired immunity: Defining a role for Il-6

10.4049/jimmunol.175.6.3463 · 2005 · External reference

Novel P19 protein engages Il-12p40 to form a cytokine, Il-23, with biological activities similar as well as distinct from Il-12

10.1016/s1074-7613(00)00070-4 · 2000 · External reference

Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa

10.1038/mi.2009.100 · 2009 · External reference

Granulocyte-macrophage colony stimulatory factor enhances the pro-inflammatory response of interferon-Γ-treated macrophages to Pseudomonas aeruginosa infection

10.1371/journal.pone.0117447 · 2015 · External reference

Il-22 plays a critical role in maintaining epithelial integrity during pulmonary infection

10.3389/fimmu.2020.01160 · 2020 · External reference

Interleukin-22 level is negatively correlated with neutrophil recruitment in the lungs in a Pseudomonas aeruginosa pneumonia model

10.1038/s41598-017-11518-0 · 2017 · External reference

Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia

10.1164/rccm.201202-0182oc · 2012 · External reference

Il-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa

10.4049/jimmunol.181.7.4965 · 2008 · External reference

Development of a chimeric vaccine against Pseudomonas aeruginosa based on the Th17-stimulating epitopes of Pcrv and Ampc

10.3389/fimmu.2020.601601 · 2020 · External reference

Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal Iga and Th17 responses

10.1038/s41598-020-63998-2 · 2020 · External reference

Il-22 mediates mucosal host defense against gram-negative bacterial pneumonia

10.1038/nm1710 · 2008 · External reference

Immune system dynamics in response to Pseudomonas aeruginosa biofilms

10.1038/s41522-025-00738-2 · 2025 · External reference

Relationship between serum Tnf-A, Il-6, and Il- 10 levels and disease severity, and changes in the cytokines after treatment in patients with bacterial community-acquired pneumonia

10.18332/pne/170181 · 2023 · External reference

Macrophage-derived cytokines in pneumonia: Linking cellular immunology and genetics

10.1016/j.cytogfr.2020.11.003 · 2021 · External reference